The identification of hormone receptors, human epidermal growth factor receptor 2 (HER2), and trophoblast cell-surface antigen 2 (Trop-2) has enabled a personalized selection of treatment for breast cancer. This evidence concerns the gene TACSTD2 and breast cancer.